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from permanent surveys on medical prescription, from the
French cost per DRG database, and from various other data
sources. Perspective was that of health insurance and prices were
consequently based on reimbursement tariffs. RESULTS: From
1991 to 2002, the direct medical cost of osteoarthritis in France
has raised by 156% (from 0.64 to 1.64 billion Euros), i.e 9%
per year. The number of treated patients increased by 54% (from
3 million to 4.6 million), so that the cost per patient rose by
4.8% per year in average. Taking the GDP price index as deﬂa-
tor, the real average annual rates of growth per treated patient
were 3.3%, 0.3%, 7.4% and 3.7% respectively for total
expenses, doctors’ visits, pharmaceuticals and hospitalisations.
Sick leave cost to health insurance rose by 2.5% per year and
per patient in real terms. CONCLUSIONS: During the past
eleven years, the cost of osteoarthritis has substantially raised in
France. Half of the growth was attributable to the number of
treated patients and to general inﬂation, the other half being due
to changes in the treatment patterns, especially in pharmaceuti-
cal prescriptions. The emergence of new treatments such as
COX-2 inhibitors may largely explain this tendency. Hospital
costs also showed a marked growth, certainly due to the gener-
alisation of hip or knee arthroplasty surgery procedures. In the
future, it may be thought that the cost will continue to grow at
a similar rate under the inﬂuence of both demographic factors
and treatment innovations.
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OBJECTIVES: We report methodology and results of a post-
launch study which was commissioned by French Health
Authorities in order to measure the effectiveness and cost of
Suplasyn(r), a hyaluronic acid indicated in the treatment of knee
osteoarthritis, in real life conditions. METHODS: An observa-
tional, multicentric, prospective, longitudinal study was designed
in order to compare pain status, functional capacity, quality of
life and cost in patients with knee osteoarthritis, before and after
treatment with Suplasyn(r). Patients should meet the American
College of Rheumatology criteria for osteoarthritis and be cur-
rently treated by analgesics or nonsteroidal anti-inﬂammatory
drugs (NSAIDs). The decision to treat with Suplasyn(r) was left
to the investigators’ discretion. Treated patients were followed
retrospectively during three months and prospectively during six
months. Main evaluations were performed at initiation (V0) and
at three (V4) and six months (V5). Cost were compared over
three 3-month periods, P1 (before Suplasyn(r) injection), P2
(V0–V4) and P3 (V4–V5). They were computed in the perspec-
tive of public health insurance. RESULTS: In total, 296 patients
were included. Mean age was 68.67 ± 10.26 years. The main
clinical criterion, the WOMAC score, showed a signiﬁcant
improvement for both functional and pain subscales over the
time: scores at V4 and V5 were signiﬁcantly reduced compared
to V0 (p < 0.0001). The SF-12 Quality-of-Life scale was signif-
icantly improved for “physical” (p < 0.0001) and “mental” (p <
0.0001) dimensions. Between P1 and P3, the proportions of
patients receiving NSAIDs and Proton Pump Inhibitors fell
respectively from 68.6% to 29.1%, and from 19.3% to 8.7% (p
< 0.0001). Finally, the average medical cost per patient decreased
from 233.59 EUR (IC95%: 202.14–265.04) in P1 to 205.64
(IC95%: 191.70–219.57) in P2 and to 145.20 (IC95%:
77.36–213.05) in P3. CONCLUSIONS: In real life conditions,
Suplasyn(r) signiﬁcantly improves function, pain and quality-of-
life of patients with knee osteoarthritis and reduces medical
treatment cost.
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OBJECTIVE: The aim of this study was to compare the eco-
nomic consequences of the treatment of elderly patients with
selective COX-2 inhibitors (Celecoxib and Rofecoxib) and non-
selective NSAIDs. METHODS: A cost-effectiveness analysis
compared costs and effects of Celecoxib versus NSAIDs, versus
Diclofenac plus Misoprostol and versus Rofecoxib in the per-
spective of the Italian National Health Service (NHS). Effects
were derived from the study of Mamdani and colleagues (BNJ
2002; 325:624–627). Direct costs were measured (hospitalisa-
tion and pharmacological costs). Pharmacological costs were
quantiﬁed according to the Italian market price of the drugs.
Hospitalisation costs were quantiﬁed on the basis of DRG tariffs.
Effects were expressed as reduction in hospitalisation for upper
gastrointestinal haemorrhage. The mean duration of follow-up
was 12 months. A sensitivity analysis was conducted on unit cost
of drugs and hospitalisations. RESULTS: Clinical effects of treat-
ing an hypothetical cohort of 1000 patients for up to 12 months
with Celecoxib would correspond to an extra cost of 29.256,98€
and of 39.120,09€ per bleeding avoided compared to NSAIDs
and of 19.157,27€ and of 33.951,94€ per bleeding avoided com-
pared to Diclofenac/Misoprostol. The therapy with Celecoxib
dominates Rofecoxib as it is less costly and more effective. CON-
CLUSIONS: Treating subjects aged ≥66 years with Celecoxib is
more effective but also more costly than with NSAIDs and with
Diclofenac plus Misoprostol. On the contrary, treating elderly
subjects with Celecoxib is not only more effective but also less
costly than with Rofecoxib.
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OBJECTIVE: To evaluate the cost of treatment of FS in Italy and
its determinants. METHODS: Multicenter retrospective cost of
care study with patients enrolled from 28 Italian rheumatologic
centers. Time: 12 months. Cost: we quantiﬁed direct costs attrib-
utable to FS management: drugs, hospitalisations, physicians’
visits, diagnostic tests, and other medical services (e.g.
ionophoresis, mesotherapy, massage, thermal baths). Costs were
estimated applying the National Health Service (NHS) tariffs
expressed in Euro 2001. Perspective: NHS and patients perspec-
tive. RESULTS: We enrolled 402 patients with FS (mean age 48.4
± 12.3 years old), 94.8% women. The mean annual cost per
patient was euro 880.1 ± 1007.5: 33.7% attributable to hospi-
talisations, 17.45% to drugs and 17.7% to other pain coping
strategies. Anti-inﬂammatory drugs were the mainly used drugs
(72.1% of the patients used anti-inﬂammatory drugs). CON-
CLUSION: The cost of ﬁbromyalgia treatment was estimated for
the ﬁrst time in Italy. The mean yearly cost is 880€ and it is prin-
cipally caused by high use of symptomatic drugs and other pain
coping strategies.
